Bio-Pharm Solutions Co. Ltd. is a pharmaceutical company focused on developing new drugs targeting the central nervous system (CNS) and rare diseases. One of its key candidate compounds, JBPOS0101, is specifically designed for the treatment of infantile spasms and partial onset seizures, conditions that currently lack effective treatments and often rely on adult medications that can have severe side effects. The company has received Orphan Drug Designation from the US FDA for JBPOS0101 and is actively conducting clinical trials in both the United States and Korea. This compound is part of a broader pipeline that includes treatments for various neurological and psychiatric disorders, as well as pain management.

In addition to JBPOS0101, Bio-Pharm Solutions is expanding its research to include other indications and has plans for global collaboration. The company has signed a licensing agreement with Jingxin Pharmaceutical Co., Ltd. for the exclusive development and commercialization of JBPOS0101 in the Chinese market, which includes significant financial milestones tied to the drug's clinical development. Bio-Pharm Solutions is also pursuing additional partnerships with global pharmaceutical companies to further its research and development efforts, aiming to establish itself as a leader in specialty pharmaceuticals within the global market.

South Korea

Bio-Pharm Solutions is a new drug developer specializing in the central nervous system and rare diseases.

Cancer

Central Nervous System (CNS)

Genetic Diseases

Nervous System Diseases

Psychological Diseases

Bio-Pharm Solutions

Infantile spasms

JBPOS0101(ADD417090)

Small Molecule Pharmaceuticals

Epilepsy

Alzheimer's disease

Refractory Status Epilepticus

Biologics

Parkinson's disease

Postpartum depression

ADD422007

Lennox-Gastaut syndrome

ADD447011, ADD446019

ADD485002

ADD428012, ADD532005

Therapeutic

Bio-Pharm Solutions

Company Details